Contact:
4008465777
-
About Us
News & Events
-
06-10
Tonghua Dongbao announces NMPA acceptance of its NDA application for repaglinide tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) received the notification of acceptance from the National Medical Products Administration (NMPA) on the NDA application...
-
04-26
Tonghua Dongbao sees accelerated profit growth recording YoY increase of 21.33% in Q1 2021
On the evening of April 26, Tonghua Dongbao (SH.600867, hereinafter referred to as the "Company") released its quarterly report for Q1 2021. In Q1 2021, the Company recorded operating revenue of RMB 823 million...
-
04-22
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for novel triple-target inhibitor
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company”) received the acceptance notification...
-
04-15
Tonghua Dongbao reports YoY increase of 14.63% in annual net profit 2020
On the evening of April 15, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2020 annual report, disclosing that the Company...
-
03-05
Tonghua Dongbao partners WuXi AppTec to develop novel drugs
On March 5, 2021, Tonghua Dongbao and WuXi AppTec signed a strategic cooperation memorandum and a contract for the development of three Class 1 new diabetes drugs in Shanghai. Mr. Leng Chunsheng...
-
01-26
Tonghua Dongbao’s strategic partner Adocia reports positive clinical trial results for BC Lispro
On January 26 (Beijing time), Adocia, a biotechnology company focused on the treatment of diabetes and other metabolic diseases, announced positive results of its clinical trial of the ultra-rapid-acting insulin lispro...